Patent US3752850A successfully refreshed from Google Patents.
Patent US2136301A successfully refreshed from Google Patents.
Patent EP0250088A2 successfully refreshed from Google Patents.
EP0250088A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of tetrahydrocortisol in glaucoma therapy
Assignee: New York Medical College
•
Filing: 1987-05-15
•
Granted: —
•
Expires: 2007-05-15
Abstract
Abstract Pharmaceutical compositions comprising tetrahydrocortisol and a method of using it in the control of intraocular pressure are disclosed.
Inventors
- 👤 Aaron Louis Southren
- 👤 Bernard I. Weinstein
- 👤 Gary G. Gordon
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-28 10:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61P; A61P27/00; A61P27/02; A61P27/06
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
31 words
A pharmaceutical composition for controlling intraocular pressure, characterized in that it comprises an intraocular pressure lowering amount of tetrahydrocortisol, or an ophthalmically acceptable salt form thereof and a pharmaceutical carrier therefor.
Claim 2
Dependent Claim
31 words
A pharmaceutical composition for controlling intraocular pressure, characterized in that it comprises an intraocular pressure lowering amount of tetrahydrocortisol, or an ophthalmically acceptable salt form thereof and a pharmaceutical carrier therefor.
Claim 3
Dependent Claim
16 words
A composition according to claim 1, characterized in that it is adapted to control ocular hypertension.
Claim 4
Dependent Claim
24 words
A composition according to claim 1, characterized in that the amount of tetrahydrocortisol is from about 0.05% by weight to about 5.0% by weight.
Claim 5
Dependent Claim
24 words
A composition according to claim 3, characterized in that the amount of tetrahydrocortisol is from about 0.5% by weight to about 3.0% by weight.
Claim 6
Dependent Claim
16 words
A composition according to claim 1 characterized in that the composition is an eye drop suspension.
Claim 7
Dependent Claim
14 words
A composition according to claim 1, characterized in that the composition is an ointment.
Claim 8
Dependent Claim
15 words
A composition according to claim 1, characterized in that the composition is an ophthalmic gel.
Claim 9
Dependent Claim
29 words
A pharmaceutical composition for controlling intraocular pressure comprising an intraocular pressure lowering amount of A-ring reductase inhibitor or an ophthalmically acceptable salt form thereof and a pharmaceutical carrier therefor.
Claim 10
Dependent Claim
29 words
A pharmaceutical composition for controlling intraocular pressure comprising an intraocular pressure lowering amount of A-ring reductase inhibitor or an ophthalmically acceptable salt form thereof and a pharmaceutical carrier therefor.
Claim 11
Independent Claim
32 words
A method of controlling intraocular pressure characterized in that it comprises topically administering to an affected eye an intraocular pressure lowering effective amount of tetrahydrocortisol, or an ophthalmically acceptable salt form thereof.
Claim 12
Independent Claim
32 words
A method of controlling intraocular pressure characterized in that it comprises topically administering to an affected eye an intraocular pressure lowering effective amount of tetrahydrocortisol, or an ophthalmically acceptable salt form thereof.
Claim 13
Dependent Claim
15 words
A method according to claim 9, characterized in that tetrahydrocortisol is the 3-alpha, 5-beta-tetrahydrocortisol stereoisomer.
Claim 14
Dependent Claim
24 words
A method according to claim 9, characterized in that the amount of tetrahydrocortisol is from about 0.05% by weight to about 5.0% by weight.
Claim 15
Dependent Claim
24 words
A method according to claim 9, characterized in that the amount of tetrahydrocortisol is from about 0.5% by weight to about 3.0% by weight.
Claim 16
Independent Claim
31 words
A method of controlling intraocular pressure comprising topically administering to an affected eye an intraocular pressure lowering effective amount of an A-ring reductase inhibitor or an ophthalmically acceptable salt form thereof.
Claim 17
Independent Claim
31 words
A method of controlling intraocular pressure comprising topically administering to an affected eye an intraocular pressure lowering effective amount of an A-ring reductase inhibitor or an ophthalmically acceptable salt form thereof.
Claim 18
Dependent Claim
15 words
A method according to claim 13, characterized in that the A-ring reductase inhibitor is progesterone.
Claim 19
Dependent Claim
15 words
A method according to claim 14, characterized in that the A-ring reductase inhibitor is testosterone.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.